2020 연구성과 (56 / 270)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
WoS SCOPUS Document Type Document Title Abstract Authors Affiliation ResearcherID (WoS) AuthorsID (SCOPUS) Author Email(s) Journal Name JCR Abbreviation ISSN eISSN Volume Issue WoS Edition WoS Category JCR Year IF JCR (%) FWCI ⓘ FWCI Update Date WoS Citation SCOPUS Citation Keywords (WoS) KeywordsPlus (WoS) Keywords (SCOPUS) KeywordsPlus (SCOPUS) Language Publication Stage Publication Year Publication Date DOI JCR Link DOI Link WOS Link SCOPUS Link
○ ○ Article ⓘ Efficacy and Safety of CKD-11101 (Proposed Biosimilar of Darbepoetin-Alfa) Compared with Darbepoetin-Alfa in Patients on Hemodialysis: A Randomized, Double-Blinded, Parallel-Group Phase III Study ⓘ Background Darbepoetin-alfa is an erythropoiesis-stimulating agent (ESA) with a long elimination half-life that achieves better hemoglobin (Hb) stability than short-acting ESAs. Objective We aimed to evaluate the efficacy and safety of intravenous CKD-11101 (a biosimilar of darbepoetin-alfa) compared with those of darbepoetin-alfa in hemodialysis patients. Methods The study was performed in 24 centers in Korea between June 2015 and June 2017. The study subjects were randomized in a double-blind manner. The follow-up duration was 24 weeks, which consisted of 20 weeks of maintenance and 4 weeks of evaluation period. All patients underwent a stabilization period to achieve a target baseline Hb of 10-12 g/dL before randomization. Following randomization, patients received darbepoetin-alfa or CKD-11101 weekly or biweekly. Results A total of 403 patients were randomized into two groups, and a total of 325 patients (80.6%) completed the investigation. The differences between the two groups in terms of change in the average Hb level from baseline to evaluation were not significant. The average administered dose of ESA was similar between the groups. There was no difference in the proportion of patients who maintained the target Hb during the evaluation period [60.4% vs. 66.2% in the CKD-11101 and darbepoetin-alfa groups, respectively (p = 0.3038)]. In addition, the safety analysis, consisting of adverse events and adverse drug reactions, showed comparable results between the two groups. Conclusion The changes in the level of Hb, dose of erythropoietin, and achievement rate of the target Hb during the study period were comparable between the groups. CKD-11101 has an equivalent efficacy and safety compared with darbepoetin-alfa in patients undergoing hemodialysis. ⓘ Kim, Yaerim; Park, Su-Kil; Cho, Won Yong; Joo, Kwon Wook; Shin, Sug Kyun; Kim, Dae Joong; Kim, Yong-Lim; Son, Sung Hyun; Chung, Wookyung; Lee, Kwang Young; Park, Sung Kwang; Kim, Joong Kyung; Kim, Soo Wan; Kang, Duk-Hee; Kim, Jin Kuk; Jeon, Jin Seok; Lee, Kang Wook; Lee, Chang Hwa; Oh, Dong-Jin; An, Won Suk; Lee, Jong Soo; Kang, Gun Woo; Do, Jun-young; Lee, Jung Pyo; Jin, Kyubok ⓘ Keimyung Univ, Dept Internal Med, Div Nephrol, Sch Med, 1035 Dalgubeol Daero, Daegu 42601, South Korea; Univ Ulsan, Asan Med Ctr, Dept Internal Med, Coll Med, Seoul, South Korea; Korea Univ, Dept Internal Med, Med Coll, Seoul, South Korea; Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Natl Hlth Insurance Corp, Dept Internal Med, Ilsan Hosp, Goyang, Gyeonggi Do, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Sch Med, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Suyeong Hanseo Hosp, Dept Internal Med, Busan, South Korea; Gachon Univ Med & Sci, Gil Med Ctr, Dept Internal Med, Seongnam, South Korea; Presbyterian Med Ctr, Dept Internal Med, Jeonju, South Korea; Chonbuk Natl Univ, Res Inst Clin Med, Dept Internal Med, Med Sch, Jeonju, South Korea; Bong Seng Hosp, Dept Internal Med, Busan, South Korea; Chonnam Natl Univ, Dept Internal Med, Med Sch, Gwangju, South Korea; Ewha Womans Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Soonchunhyang Univ, Dept Internal Med, Coll Med, Bucheon, South Korea; Soonchunhyang Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Chungnam Natl Univ Hosp, Dept Internal Med, Daejeon, South Korea; Hanyang Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Hanyang Univ, Myongji Hosp, Dept Internal Med, Coll Med, Goyang, South Korea; Dong A Univ, Dept Internal Med, Coll Med, Busan, South Korea; Ulsan Univ Hosp, Dept Internal Med, Ulsan, South Korea; Catholic Univ Daegu, Dept Internal Med, Sch Med, Daegu, South Korea; Yeungnam Univ, Dept Internal Med, Sch Med, Daegu, South Korea; SMG SNU Boramae Med Ctr, Seoul, South Korea ⓘ Kim, Sang/J-5399-2012; Joo, Kwon/J-5675-2012; Lee, Yun/J-1260-2014; Kim, Yong-Lim/AGK-3172-2022; Lee, Hye-Young/JEP-8044-2023; Kim, Nan/T-8627-2019; Kim, Dong Ki/J-5389-2012; Lee, Jun-Young/N-5963-2019; Kim, Jae-Hong/B-2530-2009 ⓘ 57202790600; 18438447500; 7401774683; 7101808967; 57207791472; 55742992100; 55633533600; 57211914410; 56963220900; 55770426000; 57203275923; 59089152700; 56108124300; 17233695600; 57191681846; 36120293400; 7501514537; 55770260300; 57197554134; 57215052077; 57201264463; 55667619200; 7006754007; 56028990400; 55050687400 ⓘ mdjin922@gmail.com; ⓘ BIODRUGS ⓘ BIODRUGS ⓘ 1173-8804 1179-190X 34 1 SCIE IMMUNOLOGY;ONCOLOGY;PHARMACOLOGY & PHARMACY ⓘ 2020 5.807 14.7 0.27 2025-06-25 ⓘ 2 3 ⓘ CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR-DISEASE; ANEMIA MANAGEMENT; HEMOGLOBIN LEVEL; MORTALITY; OUTCOMES; VARIABILITY; DIALYSIS; ASSOCIATIONS; MORBIDITY ⓘ ⓘ Adult; Biosimilar Pharmaceuticals; Darbepoetin alfa; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Epoetin Alfa; Female; Hemoglobins; Humans; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; biosimilar agent; ckd 11101; hemoglobin; recombinant erythropoietin; unclassified drug; biosimilar agent; hemoglobin; recombinant erythropoietin; adult; aged; Article; controlled study; double blind procedure; drug efficacy; drug safety; drug screening; elimination half-life; female; follow up; gastrointestinal disease; hemodialysis; hemodialysis patient; human; infection; injury; intoxication; Korea; major clinical study; male; multicenter study; neurologic disease; perception deafness; phase 3 clinical trial; priority journal; randomization; randomized controlled trial; respiratory tract disease; risk assessment; treatment duration; vascular disease; adverse drug reaction; chronic kidney failure; clinical trial; hemodialysis; metabolism; middle aged; procedures ⓘ English 2020 2020-02 10.1007/s40259-019-00396-9 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications ⓘ Janus kinase inhibitors [JAKi] are a new class of small molecule drugs that modulate inflammatory pathways by blocking one or more JAK receptors, and are increasingly being used in the treatment of immune-mediated diseases. Tofacitinib, a non-selective JAKi, is now approved for moderate-to-severe ulcerative colitis [UC] that is refractory or intolerant to tumour necrosis factor inhibitors [TNFi]. Whereas tofacitinib is associated with the advantages of oral administration, rapid onset of action, and lack of immunogenicity over TNFi, there are many safety considerations to take into account such as the risk of thromboembolism, infections, and hyperlipidaemia: each with specific nuances pertaining to prevention and monitoring strategies. Considerations such as pregnancy, breastfeeding, and history of malignancy also are to be navigated with utmost caution, given that very few data are available for guidance. With the use of JAKi in the real world progressively over time, safety implications will become more lucid, including caveats pertaining to JAK selectivity and gut-selective JAKi, as well as mechanistic data pertaining to adverse effects. This Viewpoint serves as a practical guide for clinicians managing inflammatory bowel disease [IBD] patients to navigate safety concerns around JAKi, including preventive and monitoring strategies. ⓘ Agrawal, Manasi; Kim, Eun Soo; Colombel, Jean-Frederic ⓘ Icahn Sch Med Mt Sinai, Dr Henry D Janowitz Div Gastroenterol, 1 Gustave L Levy Pl, New York, NY 10029 USA; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Div Gastroenterol, Daegu, South Korea ⓘ ⓘ 57213877152; 57203086704; 7102945104 ⓘ manasi.agrawal@mountsinai.org; ⓘ JOURNAL OF CROHNS & COLITIS ⓘ J CROHNS COLITIS ⓘ 1873-9946 1876-4479 14 SCIE GASTROENTEROLOGY & HEPATOLOGY ⓘ 2020 9.071 14.7 3.03 2025-06-25 ⓘ 58 61 Inflammatory bowel diseases; ulcerative colitis; JAK inhibitors; tofacitinib; drug safety; adverse effects; monitoring; preventive; clinical care ⓘ JANUS KINASE INHIBITOR; RHEUMATOID-ARTHRITIS; HERPES-ZOSTER; CROHNS-DISEASE; DOUBLE-BLIND; TOFACITINIB; EFFICACY; MANAGEMENT; OUTCOMES; THERAPY ⓘ Adverse effects; Clinical care; Drug safety; Inflammatory bowel diseases; JAK inhibitors; Monitoring; Preventive; Tofacitinib; Ulcerative colitis ⓘ Breast Feeding; Colitis, Ulcerative; Female; Herpes Zoster; Humans; Hyperlipidemias; Janus Kinase Inhibitors; Pregnancy; Venous Thromboembolism; 6 mercaptopurine derivative; antilipemic agent; antivirus agent; baricitinib; biological product; corticosteroid derivative; creatine kinase; filgotinib; hemoglobin; infliximab; isoniazid; Janus kinase inhibitor; nonsteroid antiinflammatory agent; nucleotide derivative; placebo; tofacitinib; tumor necrosis factor inhibitor; upadacitinib; varicella zoster vaccine; Janus kinase inhibitor; appendicitis; Article; body weight disorder; breast feeding; cancer risk; cardiovascular disease; cardiovascular risk; Clostridium difficile infection; colitis; congenital malformation; creatine kinase blood level; Crohn disease; deep vein thrombosis; digestive system perforation; drug monitoring; drug safety; drug withdrawal; encephalitis; fetotoxicity; fetus mortality; hepatitis B; herpes zoster; histoplasmosis; human; hyperlipidemia; hypertransaminasemia; incidence; infection; latent tuberculosis; lung embolism; lymphocyte count; malignant neoplasm; meta analysis (topic); neutrophil count; newborn death; non melanoma skin cancer; nonhuman; perianal abscess; phase 2 clinical trial (topic); phase 3 clinical trial (topic); platelet count; pregnancy; psoriasis; pulmonary cryptococcosis; randomized controlled trial (topic); rheumatoid arthritis; side effect; small intestine perforation; teratogenicity; thromboembolism; treatment outcome; ulcerative colitis; venous thromboembolism; virus hepatitis; female; herpes zoster; hyperlipidemia; ulcerative colitis; venous thromboembolism ⓘ English 2020 2020-07 10.1093/ecco-jcc/jjaa017 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea ⓘ Background: Lenvatinib, an oral multikinase inhibitor, is the latest addition to the treatment options for radioactive iodine (RAI)-refractory progressive differentiated thyroid carcinoma (DTC). This study investigated the efficacy of lenvatinib in real-world practice and prognostic biomarkers of survival. Methods: This multicenter study included 43 patients receiving lenvatinib as first-line or second-line treatment after sorafenib for RAI-refractory DTC. Progression-free survival (PFS) was evaluated according to various clinical factors including thyroglobulin doubling time (TgDT), tumor volume DT (TVDT), and tumor growth slope (TGS; slope of tumor change rate). Results: Patients were treated with lenvatinib for a median of 14 months; 32 were previously treated with sorafenib. The median follow-up from lenvatinib initiation to the last censoring or death was 16 months. The median starting dose of 20 mg was reduced to a median sustainable dose of 10 mg in accordance with patient adverse events (AEs). The median PFS was 21.8 months; the median overall survival was not reached. The disease control rate was 97.7%, with the first objective response at 3.8 months. PFS was not significantly associated with previous sorafenib treatment, metastatic sites, or sustainable dose. TGS measured before (TGS(pre), p = 0.003) and after (TGS(post), p = 0.036) the initiation of lenvatinib was associated with PFS. The sum of the largest diameters of target lesions (p = 0.043) and TgDT (p = 0.024) were associated with PFS, but TVDT calculated before (TVDTpre, p = 0.923) or after (TVDTpost, p = 0.966) lenvatinib treatment did not impact PFS. Lenvatinib was withdrawn in 24 patients (55.8%): in 6 patients because of treatment-induced AEs and in 18 patients because of disease progression or poor performance status. AEs of any grade were reported in all patients, and grade 3-4 AEs in 23.2% of the patients. The most frequent AE was fatigue or asthenia. Conclusions: Our results indicate that reduced doses of lenvatinib triggered by emergent AEs did not abrogate its apparent efficacy in patients with RAI-refractory DTCs. Rather, the sustained use of reduced doses of lenvatinib with a low rate of severe AEs may have contributed to the favorable outcomes. TgDT and TGS can assist in predicting the outcomes in these patients. ⓘ Song, Eyun; Kim, Mijin; Kim, Eui Young; Kim, Bo Hyun; Shin, Dong Yeob; Kang, Ho-Cheol; Ahn, Byeong-Cheol; Kim, Won Bae; Shong, Young Kee; Jeon, Min Ji; Lim, Dong Jun ⓘ Univ Ulsan, Asan Med Ctr, Coll Med, Dept Internal Med,Div Endocrinol & Metab, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea; Pusan Natl Univ Hosp, Biomed Res Inst, Dept Internal Med, Div Endocrinol & Metab, Busan, South Korea; Dongnam Inst Radiol & Med Sci, Canc Ctr, Dept Endocrinol, Busan, South Korea; Yonsei Univ, Severance Hosp, Coll Med, Dept Internal Med,Div Endocrinol & Metab, Seoul, South Korea; Chonnam Natl Univ, Hwasun Hosp, Dept Internal Med, Div Endocrinol & Metab, Chungnam, South Korea; Kyungpook Natl Univ Hosp, Dept Nucl Med, Daegu, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med,Div Endocrinol & Metab, Seoul 06591, South Korea ⓘ ; Kim, Won Gu/AAG-2096-2019; Kang, Ho-Cheol/E-7969-2011; Jeon, Minji/HTN-4703-2023; Lim, DJ/JED-5922-2023; Kim, Yong-Tae/HQZ-0240-2023 ⓘ 57192671565; 57203466579; 55315740200; 56551637500; 26434958900; 8400902400; 7202791511; 57051755500; 55666419000; 50361668300; 56405024100 ⓘ mj080332@gmail.com;ldj6026@catholic.ac.kr; ⓘ THYROID ⓘ THYROID ⓘ 1050-7256 1557-9077 30 5 SCIE ENDOCRINOLOGY & METABOLISM ⓘ 2020 6.568 14.7 2.23 2025-06-25 ⓘ 41 38 lenvatinib; radioiodine-refractory differentiated thyroid carcinoma; progression-free survival ⓘ DOUBLING-TIME; CANCER; PAPILLARY; PHASE-3; METASTASES ⓘ lenvatinib; progression-free survival; radioiodine-refractory differentiated thyroid carcinoma ⓘ Aged; Antineoplastic Agents; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Phenylurea Compounds; Progression-Free Survival; Quinolines; Republic of Korea; Retreatment; Survival Rate; Thyroid Neoplasms; Treatment Outcome; lenvatinib; radioactive iodine; sorafenib; thyroglobulin; antineoplastic agent; carbanilamide derivative; lenvatinib; quinoline derivative; radioactive iodine; aged; Article; asthenia; bronchopleural fistula; cancer control; cancer growth; cancer prognosis; cancer size; cancer survival; clinical article; cohort analysis; decreased appetite; diarrhea; differentiated thyroid cancer; drug dose reduction; drug efficacy; drug withdrawal; fatigue; female; follow up; hand foot syndrome; human; hypertension; male; median survival time; metastasis; nausea; overall survival; priority journal; progression free survival; proteinuria; retrospective study; side effect; South Korea; stomatitis; treatment response time; clinical trial; middle aged; mortality; multicenter study; retreatment; survival rate; thyroid tumor; treatment outcome ⓘ English 2020 2020-05-01 10.1089/thy.2019.0476 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Lower Glucose Level Associated With Increased Risk for Post-Dural Puncture Headache ⓘ Objective and Background Post-dural puncture headache is the most common significant adverse event following lumbar puncture. In this study, we investigated the possible systemic factors associated with risk for post-dural puncture headache (PDPH). Methods We performed a retrospective cohort study in 969 patients who underwent diagnostic lumbar puncture following a standardized protocol. We compared the clinical and laboratory profiles of the post-dural puncture headache group and non-headache group. We also identified independent factors associated with the incidence of post-dural puncture headache. Results A total of 48 patients (5%) reported headache; 12 of these patients (25%) received a therapeutic epidural blood patch and the remaining 36 patients improved with conservative treatment. After adjusting for other variables that could be related to PDPH, we found that the development of post lumbar puncture headache was independently associated with age (OR: 0.97, 95% CI: 0.95-0.99, P = .001) and serum glucose levels (OR: 0.98, 95% CI: 0.97-0.99, P = .008).When the patients were classified by age, serum glucose levels were persistently lower in patients with PDPH vs those patients without PDPH in all age groups, with more clearly significant differences observed in the elderly (age 60 years, 111.8 mg/dL vs 137.3 mg/dL, P = .023). Conclusions Low glucose levels were inversely associated with risk for post-dural puncture headache. Patients with low serum glucose should be carefully monitored for headache after lumbar puncture. ⓘ Hwang, Jaechun; Lim, Yong-Hyun; Eun, Mi-Yeon; Jeon, Ji-Ye; Ko, Pan-Woo; Kim, Sung-Hee; Kang, Kyunghun; Lee, Ho-Won; Park, Jin-Sung ⓘ Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Neurol, 807 Hoguk Ro, Daegu, South Korea; Kyungpook Natl Univ, Ctr Self Organizing Software Platform, Daegu, South Korea ⓘ Eun, Mi-Yeon/AAV-2877-2021 ⓘ 54980345300; 57202416711; 36463396500; 59274002200; 55543341200; 55718655600; 55365592200; 35337240700; 44061744500 ⓘ jinforeva@gmail.com; ⓘ HEADACHE ⓘ HEADACHE ⓘ 0017-8748 1526-4610 60 9 SCIE CLINICAL NEUROLOGY ⓘ 2020 5.887 14.7 0.16 2025-06-25 ⓘ 2 2 post-dural puncture headache; spinal puncture; cerebrospinal fluid; intracranial hypotension; hypoglycemia ⓘ LUMBAR PUNCTURE; POSTLUMBAR; PREVENTION; NEEDLE; HYPOGLYCEMIA; MANAGEMENT; DIAGNOSIS ⓘ cerebrospinal fluid; hypoglycemia; intracranial hypotension; post-dural puncture headache; spinal puncture ⓘ Adult; Age Factors; Aged; Blood Glucose; Blood Patch, Epidural; Female; Humans; Male; Middle Aged; Post-Dural Puncture Headache; Prospective Studies; Registries; Risk; glucose; adult; Article; blood patch; cerebrospinal fluid; cohort analysis; female; glucose blood level; human; incidence; laboratory; lumbar puncture; major clinical study; male; postdural puncture headache; priority journal; retrospective study; risk factor; age; aged; blood patch; middle aged; postdural puncture headache; prospective study; register; risk ⓘ English 2020 2020-10 10.1111/head.13850 ⓘ 바로가기 바로가기 바로가기 바로가기
○ Article ⓘ Safety and Optimal Timing of BCG Vaccination in Infants Born to Mothers Receiving Anti-TNF Therapy for Inflammatory Bowel Disease ⓘ Backgrounds and Aims: We aimed to evaluate the safety of Bacille Calmette-Guerin [BCG] vaccination in infants born to mothers receiving anti-tumour necrosis factor [anti-TNF] therapy for inflammatory bowel disease. Methods: Adverse events of BCG vaccination were evaluated in 90 infants who were last exposed to anti-TNF agents at a median of gestational week 30. Results: After receiving BCG vaccination at a median age of 6 months [range, 0.25-11 months], three infants [3.3%] showed injection site swelling, two of whom also showed axillar lymphadenopathy. The rates of adverse events were similar between infants who were last exposed to anti-TNF agents before the third trimester [n = 35] and those who were last exposed in the third trimester [n = 55] [2.9% vs 3.6%; p = 1.00]. All adverse events were spontaneously resolved and there were no serious adverse events such as active tuberculosis infection or death. Conclusions: BCG vaccination after 6 months of age is of low risk in infants exposed to anti-TNF agents in utero. ⓘ Park, Sang Hyoung; Kim, Hyo Jong; Lee, Chang Kyun; Song, Eun Mi; Kang, Sang-Bum; Jang, Byung Ik; Kim, Eun Soo; Kim, Kyeong Ok; Lee, Yoo Jin; Kim, Eun Young; Jung, Yun Jin; Park, Soo-Kyung; Park, Dong Il; Ye, Byong Duk; Jung, Sung-Ae; Yang, Suk-Kyun ⓘ Univ Ulsan, Asan Med Ctr, Dept Gastroenterol, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea; Kyung Hee Univ, Ctr Crohns & Colitis, Dept Gastroenterol, Coll Med, Seoul, South Korea; Ewha Womans Univ, Dept Internal Med, Sch Med, 260 Gonghangdae Ro, Seoul 07804, South Korea; Catholic Univ Korea, Coll Med, Dept Internal Med, Div Gastroenterol,Daejeon St Marys Hosp, Daejeon, South Korea; Yeungnam Univ, Dept Internal Med, Coll Med, Daegu, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, Daegu, South Korea; Keimyung Univ, Dept Internal Med, Sch Med, Daegu, South Korea; Catholic Univ, Dept Internal Med, Daegu Sch Med, Daegu, South Korea; Daegu Fatima Hosp, Dept Internal Med, Daegu, South Korea; Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Internal Med, Div Gastroenterol,Sch Med, Seoul, South Korea ⓘ ; Lee, Chang/AAI-1012-2020; Kwak, Sang Gyu/AAG-4341-2021; Park, Sang Hyoung/CAH-4735-2022; Lee, Yoojin/AAB-9799-2022; Kim, Eun Young/JCE-3602-2023; Ye, Byong/AAF-4955-2020 ⓘ ⓘ jassa@ewha.ac.kr;sky@amc.seoul.kr; ⓘ JOURNAL OF CROHNS & COLITIS ⓘ J CROHNS COLITIS ⓘ 1873-9946 1876-4479 14 12 SCIE GASTROENTEROLOGY & HEPATOLOGY ⓘ 2020 9.071 14.7 ⓘ 23 Inflammatory bowel disease; anti-tumor necrosis factor; BCG; infant ⓘ CONSENSUS ⓘ ⓘ ⓘ English 2020 2020-12 10.1093/ecco-jcc/jjaa099 ⓘ 바로가기 바로가기 바로가기
○ Meeting Abstract ⓘ The efficacy and safety of adalimumab for patients with moderately to severely active ulcerative colitis and predictors of response in Korea ⓘ ⓘ Shin, S. Shin; Park, S. J.; Kim, Y.; Im, J. P.; Kim, H. J.; Lee, K. M.; Kim, J. W.; Jung, S. A.; Lee, J.; Kang, S. B.; Shin, S. J.; Kim, E. S.; Kim, Y. S.; Kim, T. O.; Kim, H. S.; Park, D. I.; Kim, H. K.; Kim, E. S.; Kim, Y. H.; Kim, D. H.; Teng, D.; Kim, J. H.; Kim, W. Y.; Choi, C. H. ⓘ Chung Ang Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Kyung Hee Univ Hosp, Dept Gastroenterol, Seoul, South Korea; Catholic Univ Korea, St Vincents Hosp, Dept Gastroenterol, Suwon, South Korea; SMG SNU Boramae Med Ctr, Dept Gastroenterol, Seoul, South Korea; Ewha Womans Univ Hosp, Dept Gastroenterol, Seoul, South Korea; Chosun Univ, Coll Med, Dept Internal Med, Gwagju, South Korea; Catholic Univ Korea, Daejeon ST Marys Hosp, Dept Gastroenterol, Daejeon, South Korea; Ajou Univ, Sch Med, Dept Gastroenterol, Suwon, South Korea; Korea Univ, Anam Hosp, Dept Gastroenterol, Seoul, South Korea; Inje Univ, Seoul Paik Hosp, Dept Gastroenterol, Seoul, South Korea; Inje Univ, Haeundae Paik Hosp, Dept Gastroenterol, Busan, South Korea; Chonnam Natl Univ Hosp, Dept Gastroenterol, Gwagju, South Korea; Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Internal Med, Seoul, South Korea; Inha Univ Hosp, Dept Gastroenterol, Incheon, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Sungkyunkwan Univ, Sch Med, Dept Med, Seoul, South Korea; Abbvie Ltd, Seoul, South Korea; AbbVie Pte Ltd, Singapore, Singapore ⓘ Kwak, Sang Gyu/AAG-4341-2021; Kim, Jin Young/AAB-6510-2020; Kim, Bo-Hyung/JRX-0407-2023; Kim, Woo/C-1846-2011; Kim, Jin-Soo/AAF-3359-2019; Kim, Eun-young/AAI-8613-2020 ⓘ ⓘ ⓘ JOURNAL OF CROHNS & COLITIS ⓘ J CROHNS COLITIS ⓘ 1873-9946 1876-4479 14 SCIE GASTROENTEROLOGY & HEPATOLOGY ⓘ 2020 9.071 14.7 ⓘ 1 ⓘ ⓘ ⓘ ⓘ English 2020 2020-01 ⓘ 바로가기 바로가기
○ ○ Article ⓘ Antibacterial and photocatalytic activities of 5-nitroindole capped bimetal nanoparticles against multidrug resistant bacteria ⓘ The emergence of antibiotic resistance to commercially-available antibiotics is becoming a major health crisis worldwide. Non-antibiotic strategies are needed to combat biofilm-associated infectious diseases caused by multidrug resistant (MDR) bacterial pathogens. In this study, MBR1 was isolated from a membrane bioreactor used in wastewater treatment plants, and the resistance profile was explored. 5-Nitroindole (5 N)-capped CuO/ZnO bimetal nanoparticles (5 NNP) were synthesized using a one pot method to improve the antibacterial and antibiofilm activities of 5 N against Gram-negative (Escherichia coli ATCC700376 and Pseudomonas aeruginosa PA01) and positive (Staphylococcus aureus ATCC6538) human pathogens. 5 NNP containing 1 mM of 5 N exhibited strong antibacterial and antibiofilm properties to most MDR bacteria. In addition, the photocatalytic activity of CuO/ZnO reduced bacterial cell growth by 1.8 log CFU/mL maximum when exposed to visible light. Scanning electron microscopy showed that 5 NNP reduced the cell density and biofilm attachment of MBR1 by > 90% under static conditions. In addition to the antimicrobial and antibiofilm activities, 5 NNP inhibited the persister cell formation of MDR bacterial strains P. aeruginosa, MBR1, E. coli and S. aureus. Therefore, it is speculated that 5 NNP potentially inhibits biofilm and persister cells; hence, 5 NNP could be an alternative agent to combat MDR infectious diseases using a non-antibiotic therapeutic approach. ⓘ Manoharan, Ranjith Kumar; Mahalingam, Shanmugam; Gangadaran, Prakash; Ahn, Young-Ho ⓘ Yeungnam Univ, Dept Civil Engn, Gyongsan 38541, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Nucl Med, Daegu 41944, South Korea ⓘ Gangadaran, Prakash/AAV-3102-2021; Kumar, Ranjith/GYJ-4572-2022 ⓘ 57193200049; 57195068831; 54393130400; 24586951200 ⓘ yhahn@ynu.ac.kr; ⓘ COLLOIDS AND SURFACES B-BIOINTERFACES ⓘ COLLOID SURFACE B ⓘ 0927-7765 1873-4367 188 SCIE BIOPHYSICS;CHEMISTRY, PHYSICAL;MATERIALS SCIENCE, BIOMATERIALS ⓘ 2020 5.268 14.8 1.38 2025-06-25 ⓘ 30 30 Multidrug resistance bacteria; Nanoparticles; Indole; Antibiofilm; Anti-persister ⓘ BIOFILM FORMATION; ZNO NANOPARTICLES; ESCHERICHIA-COLI; ZINC-OXIDE; PERSISTER CELL; INDOLE; DERIVATIVES; INFECTIONS; TOLERANCE; COATINGS ⓘ Anti-persister; Antibiofilm; Indole; Multidrug resistance bacteria; Nanoparticles ⓘ Anti-Bacterial Agents; Catalysis; Copper; Drug Resistance, Multiple, Bacterial; Escherichia coli; Indoles; Microbial Sensitivity Tests; Nanoparticles; Particle Size; Photochemical Processes; Pseudomonas aeruginosa; Staphylococcus aureus; Surface Properties; Zinc Oxide; Antibiotics; Bimetals; Biofilms; Bioreactors; Cell proliferation; Cells; Cellular manufacturing; Copper oxides; Cytology; Diseases; Escherichia coli; Nanoparticles; Scanning electron microscopy; Synthesis (chemical); Wastewater treatment; Zinc compounds; 5 nitroindole; aminoglycoside; ampicillin; beta lactam; cefotaxime; ciprofloxacin; colistin; copper oxide nanoparticle; genomic DNA; gentamicin; gold nanoparticle; indole derivative; kanamycin; meticillin; nanoparticle; quinolone derivative; sulfamethoxazole; tetracycline; unclassified drug; vancomycin; zinc oxide nanoparticle; 5-nitroindole; antiinfective agent; copper; cupric oxide; indole derivative; nanoparticle; zinc oxide; Anti-biofilm; Anti-persister; Antibiotic resistance; Indole; Multidrug resistance; Pseudomonas aeruginosa; Staphylococcus aureus; Wastewater treatment plants; antibacterial activity; antibiotic resistance; antibiotic sensitivity; antimicrobial activity; Article; bacterial cell; bacterial strain; bacterial virulence; biofilm; cell density; controlled study; drug mechanism; Escherichia coli; Gram negative bacterium; Gram positive bacterium; light; minimum inhibitory concentration; multidrug resistant bacterium; nonhuman; photocatalysis; priority journal; Pseudomonas aeruginosa; scanning electron microscopy; Staphylococcus aureus; transmission electron microscopy; waste water management; catalysis; chemistry; drug effect; microbial sensitivity test; multidrug resistance; particle size; photochemistry; surface property; synthesis; Photocatalytic activity ⓘ English 2020 2020-04 10.1016/j.colsurfb.2020.110825 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Questionable Effect of Crosshatching Incision in Septoplasty ⓘ Objectives. Crosshatching incision has been considered a useful method for correcting cartilaginous septal deviation. The aim of this study was to determine the utility and limitations of this approach. Methods. This retrospective case-control study included 353 patients who underwent septoplasty performed by a senior surgeon between January 2004 and December 2010. Patients were classified into two groups according to whether crosshatching incision was performed (n=151) during septoplasty or not (n=202). All other techniques performed during septoplasty were identical. The parameters of surgical success (improvement of nasal obstruction, correction of deviation, and acoustic rhinometry results) and adverse effects were compared between the groups. Results. There were no significant differences in the parameters of surgical success between the groups (improvement of nasal obstruction, P=0.333; correction of deviation, P=0.608; acoustic rhinometry results, P=0.322 for the difference in the minimal cross-sectional area; P=0.919 for difference in volume). Relative to patients who did not undergo the cross-hatching incision, patients with whom the technique was performed showed a significantly higher incidence of saddle nose (0/202 vs. 4/151 cases, P=0.033) and overcorrection (0/202 vs. 5/151 cases, P=0.014). Conclusion. Crosshatching incision during septoplasty did not produce better surgical outcomes; however, it caused adverse effects such as saddle nose and overcorrection.Therefore, the use of crosshatching incision should be re-evaluated. ⓘ Kim, Jung-Soo; Heo, Sung Jae ⓘ Kyungpook Natl Univ, Sch Med, Kyungpook Natl Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Chilgok Hosp, Dept Otorhinolaryngol Head & Neck Surg, Daegu, South Korea ⓘ 허, 성재/AAU-3921-2020 ⓘ 55720132500; 55822906000 ⓘ blueskyhsj@hanmail.net; ⓘ CLINICAL AND EXPERIMENTAL OTORHINOLARYNGOLOGY ⓘ CLIN EXP OTORHINOLAR ⓘ 1976-8710 2005-0720 13 1 SCIE OTORHINOLARYNGOLOGY ⓘ 2020 3.372 14.8 0.58 2025-06-25 ⓘ 4 5 Nasal Septum; Cartilage; Nasal Surgical Procedures; Reconstructive Surgical Procedures ⓘ CARTILAGE; DEVIATION; OUTCOMES ⓘ Cartilage; Nasal septum; Nasal surgical procedures; Reconstructive surgical procedures ⓘ ⓘ English 2020 2020-02 10.21053/ceo.2019.00206 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Streptomyces sp. LH 4 promotes plant growth and resistance against Sclerotinia sclerotiorum in cucumber via modulation of enzymatic and defense pathways ⓘ Background In the soil ecosystem, microbial diversity exists and these diverse organisms interact with plant roots and influence the physicochemical properties of plants. Some of these diverse microorganisms can cause diseases or can provide beneficial interactions with plants. Rhizobacteria are well-known beneficial microorganism that colonize the plant root zone (rhizosphere) and are referred to as plant growth-promoting rhizobacteria (PGPR) that contribute to the promotion of plant growth either directly or indirectly. PGPRs are also known for their biocontrol abilities. Sclerotinia sclerotiorum, an Ascomycetous soil inhabiting fungus, causes white rot disease in cucumbers. This disease results in the loss of millions of dollars annually. The current study was conducted to isolate naturally occurring soil inhabiting bacteria that may promote plant growth under diseased conditions and also antagonize the pathogen. Scope The isolated LH4 strain was identified as Streptomyces sp. by 16S rRNA sequencing and phylogenetic analysis. The plant growth promoting effects and the antifungal antagonistic activities against Sclerotinia sclerotiorum were confirmed by measuring enzymatic activity of LH4 and demonstration in planta. In addition, Streptomyces sp. LH4 pure culture application exhibited significant growth inhibition of S. sclerotiorum in cucumber. Analysis of the major hormones related to pathogen defense; the jasmonic acid, and salicylic acid, showed that the modulation of these two hormones increased disease resistance in cucumber. Conclusion The present study suggests a possible dual role of Streptomyces sp. LH4 as functional material for bio-fertilizer and biocontrol against pathogens. ⓘ Mun, Bong-Gyu; Lee, Won-Hee; Kang, Sang-Mo; Lee, Sang-Uk; Lee, Seok-Min; Lee, Dong Yeol; Shahid, Muhammad; Yun, Byung-Wook; Lee, In-Jung ⓘ Kyungpook Natl Univ, Sch Appl Biosci, Daegu, South Korea; Environm Friendly Agr Div, Agr Res & Extens Serv, Gyeongnam, Jinju, South Korea; Gyeongnam Oriental Antiaging Inst, Gyeongnam, Sancheong, South Korea ⓘ Kang, Sang-Mo/MBG-7823-2025; Lee, In-Jung/GLS-0432-2022; Mun, BongGyu/GYD-6010-2022; Shahid, Muhammad/AAE-9424-2020 ⓘ 57147241300; 58950753600; 56189696900; 57203597131; 56735697700; 55542929300; 59577718600; 8245123600; 16425830900 ⓘ mbg@knu.ac.kr;wonheen@knu.ac.kr;kmoya@hanmail.net;2sanguk.c@gmail.com;iamleesukmin@korea.kr;7560112@naver.com;shahidariswat@gmail.com;bwyun@knu.ac.kr;ijlee@knu.ac.kr; ⓘ PLANT AND SOIL ⓘ PLANT SOIL ⓘ 0032-079X 1573-5036 448 1-2 SCIE AGRONOMY;PLANT SCIENCES;SOIL SCIENCE ⓘ 2020 4.192 14.8 2.29 2025-06-25 ⓘ 25 32 Streptomyces sp; Sclerotinia sclerotiorum; PGPR; Antifungal agents; Plant hormones; Cucumber ⓘ BIOLOGICAL-CONTROL; CONIOTHYRIUM-MINITANS; SALICYLIC-ACID; ANTAGONISTIC ACTIVITIES; ANTIFUNGAL ACTIVITY; RHIZOBACTERIA PGPR; BOTRYTIS-CINEREA; JASMONIC ACID; FUSARIUM-WILT; CAUSAL AGENT ⓘ Antifungal agents; Cucumber; PGPR; Plant hormones; Sclerotinia sclerotiorum; Streptomyces sp ⓘ Bacteria (microorganisms); Cucumis sativus; Fungi; Rhizobiales; Sclerotinia sclerotiorum; Streptomyces; Streptomyces sp.; disease resistance; enzyme activity; fungus; hormone; inhibition; microbial community; physicochemical property; rhizobacterium; rhizosphere; soil ecosystem; species diversity; vine ⓘ English 2020 2020-03 10.1007/s11104-019-04411-4 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Preparation of a mesoporous silica quorum quenching medium for wastewater treatment using a membrane bioreactor ⓘ Various quorum quenching (QQ) media have been developed to mitigate membrane biofouling in a membrane bioreactor (MBR). However, most are expensive, unstable and easily trapped in hollow fibre membranes. Here, a sol-gel method was used to develop a mesoporous silica medium entrapping a QQ bacterial strain (Rhodococcus sp. BH4). The new silica QQ medium was able to remove quorum sensing signalling molecules via both adsorption (owing to their mesoporous hydrophobic structure) and decomposition with an enzyme (lactonase), preventing MBR biofouling without affecting the water quality. It also demonstrated a relatively long life span due to its non-biodegradability and its relatively small particle size (<1.0 mm), which makes it less likely to clog in a hollow fibre membrane module. ⓘ Lee, Kibaek; Choo, Kwang-Ho; Ng, How Yong; Lee, Chung-Hak ⓘ Natl Univ Singapore, NUS Environm Res Inst, Singapore, Singapore; Kyungpook Natl Univ, Adv Inst Water Ind, Daegu, South Korea; Chonnam Natl Univ, Dept Biotechnol & Bioengn, Gwangju, South Korea; Seoul Natl Univ, Sch Chem & Biol Engn, Seoul, South Korea ⓘ Ng, How Yong/A-3153-2013; Choo, Kwang-Ho/A-3456-2016; 이, 정학/GWQ-6252-2022 ⓘ 55845961700; 7102083272; 8566852400; 7410142508 ⓘ leech@snu.ac.kr; ⓘ BIOFOULING ⓘ BIOFOULING ⓘ 0892-7014 1029-2454 36 4 SCIE BIOTECHNOLOGY & APPLIED MICROBIOLOGY;MARINE & FRESHWATER BIOLOGY ⓘ 2020 3.209 15.0 0.85 2025-06-25 ⓘ 10 14 Mesoporous silica; silica QQ media; quorum sensing; quorum quenching; biofouling; membrane bioreactor ⓘ BIOFOULING CONTROL; BACTERIA; MBR; IMMOBILIZATION; PARADIGM; STRATEGY; DESIGN ⓘ biofouling; membrane bioreactor; Mesoporous silica; quorum quenching; quorum sensing; silica QQ media ⓘ Biofouling; Bioreactors; Membranes; Membranes, Artificial; Quorum Sensing; Silicon Dioxide; Waste Disposal, Fluid; Water Purification; Bacteria (microorganisms); Rhodococcus sp.; silicon dioxide; bacterium; bioreactor; membrane; molecular analysis; silica; wastewater treatment; water quality; artificial membrane; biofouling; bioreactor; membrane; quorum sensing; sewage; water management ⓘ English 2020 2020-04-20 10.1080/08927014.2020.1749601 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ A new neuropeptide insect parathyroid hormone iPTH in the red flour beetle Tribolium castaneum ⓘ In the postgenomics era, comparative genomics have advanced the understanding of evolutionary processes of neuropeptidergic signaling systems. The evolutionary origin of many neuropeptidergic signaling systems can be traced date back to early metazoan evolution based on the conserved sequences. Insect parathyroid hormone receptor (iPTHR) was previously described as an ortholog of vertebrate PTHR that has a well-known function in controlling bone remodeling. However, there was no sequence homologous to PTH sequence in insect genomes, leaving the iPTHR as an orphan receptor. Here, we identified the authentic ligand insect PTH (iPTH) for the iPTHR. The taxonomic distribution of iPTHR, which is lacking in Diptera and Lepidoptera, provided a lead for identifying the authentic ligand. We found that a previously described orphan ligand known as PXXXamide (where X is any amino acid) described in the cuttlefish Sepia officinalis has a similar taxonomic distribution pattern as iPTHR. Tests of this peptide, iPTH, in functional reporter assays confirmed the interaction of the ligand-receptor pair. Study of a model beetle, Tribolium castaneum, was used to investigate the function of the iPTH signaling system by RNA interference followed by RNA sequencing and phenotyping. The results suggested that the iPTH system is likely involved in the regulation of cuticle formation that culminates with a phenotype of defects in wing exoskeleton maturation at the time of adult eclosion. Moreover, RNAi of iPTHRs also led to significant reductions in egg numbers and hatching rates after parental RNAi. Author summary Vertebrate parathyroid hormone (PTH) and its receptors have been extensively studied with respect to their function in bone remodeling and calcium metabolism. Insect parathyroid hormone receptors (iPTHRs) have been previously described as counterparts of vertebrate PTHRs, however, they are still orphan receptors for which the authentic ligands and biological functions remain unknown. We describe an insect form of parathyroid hormone (iPTH) by analyzing its interactions with iPTHRs. Identification of this new insect peptidergic system proved that the PTH system is an ancestral signaling system dating back to the evolutionary time before the divergence of protostomes and deuterostomes. We also investigated the functions of the iPTH system in a model beetle Tribolium castaneum by using RNA interference. RNA interference of iPTHR resulted in defects in wing exoskeleton maturation and fecundity. Based on the differential gene expression patterns and the phenotype induced by RNAi, we propose that the iPTH system is likely involved in the regulation of exoskeletal cuticle formation and fecundity in insects. ⓘ Xie, Jia; Sang, Ming; Song, Xiaowen; Zhang, Sisi; Kim, Donghun; Veenstra, Jan A.; Park, Yoonseong; Li, Bin ⓘ Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Biodivers & Biotechnol, Nanjing, Peoples R China; Kansas State Univ, Dept Entomol, Manhattan, KS 66506 USA; Kyungpook Natl Univ, Dept Appl Biol, Sangju, South Korea; Univ Bordeaux, INCIA, UMR 5287, CNRS, Pessac, France ⓘ Veenstra, Jan/B-4610-2008; Song, Xiaowen/NPJ-1174-2025; Park, Yoonseong/J-5861-2013 ⓘ 57194728937; 36009357000; 56236088300; 57201910163; 56115927500; 7006830970; 7405370790; 57129082200 ⓘ jan-adrianus.veenstra@u-bordeaux.fr;ypark@ksu.edu;libin@njnu.edu.cn; ⓘ PLOS GENETICS ⓘ PLOS GENET ⓘ 1553-7404 16 5 SCIE GENETICS & HEREDITY ⓘ 2020 5.917 15.1 1.33 2025-06-25 ⓘ 25 25 ⓘ PROTEIN-COUPLED RECEPTORS; GENOMIC ANALYSIS; FAMILY; EVOLUTION; PEPTIDE; PATHWAY; GENES; MODEL; EXPRESSION; BURSICON ⓘ ⓘ Animals; Evolution, Molecular; Insect Proteins; Neuropeptides; Parathyroid Hormone; Phenotype; Phylogeny; Receptors, Parathyroid Hormone; Sequence Analysis, RNA; Tribolium; Wings, Animal; double stranded RNA; neuropeptide; parathyroid hormone; parathyroid hormone receptor; parathyroid hormone receptor 1; parathyroid hormone receptor 2; insect protein; neuropeptide; parathyroid hormone; parathyroid hormone receptor; adult; amino terminal sequence; animal cell; Article; carboxy terminal sequence; controlled study; developmental stage; disulfide bond; down regulation; egg; gene expression regulation; hatching; immunoreactivity; nonhuman; phenotype; protein analysis; protein cleavage; protein expression; protein localization; PTH gene; PTHR1 gene; PTHR2 gene; RNA interference; RNA sequencing; sequence alignment; signal transduction; Tribolium castaneum; upregulation; anatomy and histology; animal; genetics; metabolism; molecular evolution; phylogeny; sequence analysis; Tribolium; wing ⓘ English 2020 2020-05 10.1371/journal.pgen.1008772 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Automatic, location-privacy preserving dashcam video sharing using blockchain and deep learning ⓘ Today, many people use dashcams, and videos recorded on dashcams are often used as evidence of accident fault. People can upload videos of dashcam recordings with specific accident clips and share the videos with others who request them, by providing the time or location of an accident. However, dashcam videos are erased when the dashcam memory is full, so periodic backup is necessary for video sharing. It is inconvenient for dashcam owners to search for and transmit a requested video clip from backup videos. In addition, anonymity is not ensured, which may reduce location privacy by exposing the video owner's location. To solve this problem, we propose a video sharing scheme with accident detection using deep learning coupled with automatic transfer to the cloud; we also propose ensuring data and operational integrity along with location privacy by using blockchain smart contracts. Furthermore, our proposed system uses proxy re-encryption to enhance the confidentiality of a shared video. Our experiments show that our proposed automatic video sharing system is cost-effective enough to be acceptable for deployment. ⓘ Kim, Taehyoung; Jung, Im Y.; Hu, Yih-Chun ⓘ Kyungpook Natl Univ, Sch Elect Engn, Daehakro 80, Daegu 41566, South Korea; Univ Illinois Urbana Champaign UIUC, Elect & Comp Engn Dept, 901 West Illinois St, Urbana, IL 61801 USA ⓘ ⓘ 57205366976; 18037522200; 57201948004 ⓘ iyjung@ee.knu.ac.kr; ⓘ HUMAN-CENTRIC COMPUTING AND INFORMATION SCIENCES ⓘ HUM-CENT COMPUT INFO ⓘ 2192-1962 10 1 SCIE COMPUTER SCIENCE, INFORMATION SYSTEMS ⓘ 2020 5.9 15.2 1.71 2025-06-25 ⓘ 22 25 Automation; Automotive; Data sharing; Security; Privacy; Blockchain; Deep learning ⓘ ⓘ Automation; Automotive; Blockchain; Data sharing; Deep learning; Privacy; Security ⓘ Accidents; Blockchain; Cost effectiveness; Cryptography; Location; Accident detections; IS costs; Location privacy; Proxy re encryptions; System use; Video clips; Video sharing; Video sharing systems; Deep learning ⓘ English 2020 2020-08-26 10.1186/s13673-020-00244-8 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Molecular identification of Culicoides (Diptera: Ceratopogonidae) species in Algeria ⓘ Bluetongue is a serious vector-borne viral disease that infects wild and domestic ruminants. The causative virus is transmitted by midges of the genus Culicoides, which consists of at least 1350 species worldwide. Since 1998, bluetongue disease has spread to Europe and northern Africa, including Algeria. To better understand the distribution of Culicoides species in Algeria, adult midges were collected from 17 different regions in Algeria from 2009 to 2015. At first, 492 specimens were grouped into 52 batches by wing patterns and geographic area of Algeria. Analysis of 60 nucleotide sequences of the mitochondrial cytochrome oxidase subunit I (COI) gene showed that the presence of 14 species including five unknown species, which were belonged to seven distinct subgenera. At least five species (C. imicola, C. obsoletus, C. puncticollis, C. kingi, and C. newsteadi) were discussed as potential vectors of bluetongue virus (BTV). The present study provides important insights into the genetic diversity of Culicoides and the potential spread of BTV in Algeria. ⓘ Hakima, Berrayah; Hwang, Hwal-Su; Lee, Kyeong-Yeoll ⓘ Algerian Natl Inst Vet Med, Parasitol & Histol Lab, Cent Vet Lab Algiers, Algiers, Algeria; Kyungpook Natl Univ, Coll Agr & Life Sci, Div Appl Biosci, Daegu, South Korea; Kyungpook Natl Univ, Inst Plant Med, Daegu, South Korea; Kyungpook Natl Univ, Agr Sci & Technol Inst, Daegu, South Korea ⓘ ⓘ 57211668680; 57204055221; 57217153096 ⓘ leeky@knu.ac.kr; ⓘ ACTA TROPICA ⓘ ACTA TROP ⓘ 0001-706X 1873-6254 202 SCIE PARASITOLOGY;TROPICAL MEDICINE ⓘ 2020 3.112 15.2 0.83 2025-06-25 ⓘ 7 8 Bluetongue virus; Culicoides; Genetic diversity; Genotype; Vector ⓘ BLUETONGUE-VIRUS; VECTOR COMPETENCE; IMICOLA; EUROPE ⓘ Bluetongue virus; Culicoides; Genetic diversity; Genotype; Vector ⓘ Algeria; Animals; Bluetongue; Ceratopogonidae; Genetic Variation; Insect Vectors; Algeria; Bluetongue virus; Ceratopogonidae; Chironomidae; Culicoides imicola; Culicoides newsteadi; Culicoides obsoletus; Culicoides puncticollis; Diptera; cytochrome c oxidase; cytochrome oxidase subunit 1; unclassified drug; disease vector; genetic variation; genotype; insect; molecular analysis; ruminant; viral disease; virus; adult; Algeria; animal experiment; animal tissue; Article; Bluetongue orbivirus; Culicoides; Culicoides imicola; Culicoides kingi; Culicoides newsteadi; Culicoides obsoletus; Culicoides puncticollis; female; genetic variability; molecular diagnosis; nonhuman; nucleotide sequence; nucleotide sequence; sequence analysis; species distribution; species identification; virus transmission; wing; animal; bluetongue; Ceratopogonidae; classification; genetic variation; genetics; insect vector; virology ⓘ English 2020 2020-02 10.1016/j.actatropica.2019.105261 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Characterizing Tracer Transport Behavior in Two-Phase Flow System: Implications for CO2 Geosequestration ⓘ Tracers are used to tag the injected carbon dioxide (CO2) for verification of the storage performance and containment in geosequestration. Yet the characterization of the transport behavior of a chemical tracer in two-phase flow system has not been fully investigated. We present experimental observations together with numerical results for both homogeneous and heterogeneous media from core scale to field scale. The key features of the breakthrough curves (BTCs) that include the tracer arrival time, peak concentration, and tailing pattern were examined. We identify distinct differences in BTCs depending on whether the formation was previously swept by CO2. When the tracer is released before CO2 sweeps the formation, the tracer transports at the front of gas-liquid interfaces with a narrow tracer plume distribution and the BTCs reflect the effect of local heterogeneity. Furthermore, a series of tracer pulse can be used to identify whether new pathways have been developed during CO2 injection. Plain Language Summary Geologic storage of carbon dioxide (CO2) has become an attractive climate change mitigation option, and ensuring the containment of injected CO2 is of prime importance for successful geological storage. Tracers are an effective means of tracking injected CO2 and verifying containment within the storage formation. Here we show that distinctive features in observed tracer data are highly related to whether or not the storage formation was previously swept by CO2. When the tracer is released at the beginning of CO2 injection, the tracer moves with narrow distribution and is advantageous for the tracer data to reflect multiple pathways. By contrast, once the CO2 sweeps the formation, the tracer moves much faster with a wider dispersion pattern. Key Points We present experimental observations with numerical results for characterizing the tracer transport behavior in two-phase flow system The key features of breakthrough curves and tracer velocity highly depend on whether the formation was previously swept by CO2 A series of tracer pulse can be used to identify whether new pathways have been developed during CO2 injection ⓘ Kim, Minji; Kim, Kue-Young; Kim, Chan Yeong; Chae, Gi-Tak; Han, Weon Shik; Park, Eungyu ⓘ Korea Inst Geosci & Mineral Resources, Daejeon, South Korea; Yonsei Univ, Dept Earth Syst Sci, Seoul, South Korea; Pohang Accelerator Lab, Pohang, South Korea; Kyungpook Natl Univ, Dept Geol, Daegu, South Korea ⓘ ; Han, Weon Shik/KCY-0126-2024 ⓘ 59036772400; 15029920800; 57201732408; 7006820534; 57226420125; 23995577700 ⓘ kykim@kigam.re.kr; ⓘ GEOPHYSICAL RESEARCH LETTERS ⓘ GEOPHYS RES LETT ⓘ 0094-8276 1944-8007 47 23 SCIE GEOSCIENCES, MULTIDISCIPLINARY ⓘ 2020 4.72 15.3 0.08 2025-06-25 ⓘ 3 3 Breakthrough curves; Carbon dioxide; Chemical tracer; Geosequestration; Two-phase flow ⓘ FIELD-TEST; SATURATION; CRANFIELD; INJECTION; PRESSURE; DESIGN; GAS ⓘ Breakthrough curves; Carbon dioxide; Chemical tracer; Geosequestration; Two-phase flow ⓘ Carbon dioxide; Phase interfaces; Tracers; Break through curve; Gas-liquid interface; Geo sequestrations; Heterogeneous media; Local heterogeneity; Peak concentrations; Storage performance; Transport behavior; carbon dioxide; carbon storage; experimental study; heterogeneity; plume; tracer; Two phase flow ⓘ English 2020 2020-11-28 10.1029/2020gl089262 ⓘ 바로가기 바로가기 바로가기 바로가기
○ ○ Article ⓘ Core Outcomes Set for Trials in People With Coronavirus Disease 2019 ⓘ Objectives: The outcomes reported in trials in coronavirus disease 2019 are extremely heterogeneous and of uncertain patient relevance, limiting their applicability for clinical decision-making. The aim of this workshop was to establish a core outcomes set for trials in people with suspected or confirmed coronavirus disease 2019. Design: Four international online multistakeholder consensus workshops were convened to discuss proposed core outcomes for trials in people with suspected or confirmed coronavirus disease 2019, informed by a survey involving 9,289 respondents from 111 countries. The transcripts were analyzed thematically. The workshop recommendations were used to finalize the core outcomes set. Setting: International. Subjects: Adults 18 years old and over with confirmed or suspected coronavirus disease 2019, their family members, members of the general public and health professionals (including clinicians, policy makers, regulators, funders, researchers). Interventions: None. Measurements: None. Main Results: Six themes were identified. "Responding to the critical and acute health crisis" reflected the immediate focus on saving lives and preventing life-threatening complications that underpinned the high prioritization of mortality, respiratory failure, and multiple organ failure. "Capturing different settings of care" highlighted the need to minimize the burden on hospitals and to acknowledge outcomes in community settings. "Encompassing the full trajectory and severity of disease" was addressing longer term impacts and the full spectrum of illness (e.g. shortness of breath and recovery). "Distinguishing overlap, correlation and collinearity" meant recognizing that symptoms such as shortness of breath had distinct value and minimizing overlap (e.g. lung function and pneumonia were on the continuum toward respiratory failure). "Recognizing adverse events" refers to the potential harms of new and evolving interventions. "Being cognizant of family and psychosocial wellbeing" reflected the pervasive impacts of coronavirus disease 2019. Conclusions: Mortality, respiratory failure, multiple organ failure, shortness of breath, and recovery are critically important outcomes to be consistently reported in coronavirus disease 2019 trials. ⓘ Tong, Allison; Elliott, Julian H.; Azevedo, Luciano Cesar; Baumgart, Amanda; Bersten, Andrew; Cervantes, Lilia; Chew, Derek P.; Cho, Yeoungjee; Cooper, Tess; Crowe, Sally; Douglas, Ivor S.; Evangelidis, Nicole; Flemyng, Ella; Hannan, Elyssa; Horby, Peter; Howell, Martin; Lee, Jaehee; Liu, Emma; Lorca, Eduardo; Lynch, Deena; Marshall, John C.; Gonzalez, Andrea Matus; McKenzie, Anne; Manera, Karine E.; McLeod, Charlie; Mehta, Sangeeta; Mer, Mervyn; Morris, Andrew Conway; Nseir, Saad; Povoa, Pedro; Reid, Mark; Sakr, Yasser; Shen, Ning; Smyth, Alan R.; Snelling, Tom; Strippoli, Giovanni F. M.; Teixeira-Pinto, Armando; Torres, Antoni; Turner, Tari; Viecelli, Andrea K.; Webb, Steve; Williamson, Paula R.; Woc-Colburn, Laila; Zhang, Junhua; Craig, Jonathan C. ⓘ Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, Australia; Childrens Hosp Westmead, Ctr Kidney Res, Sydney, NSW, Australia; Monash Univ, Cochrane Australia, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; Hosp Sirio Libanes, Dept Crit Care Med, Sao Paulo, Brazil; Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA, Australia; Denver Hlth, Dept Med, Denver, CO USA; Univ Queensland, Princess Alexandra Hosp, Fac Med, Brisbane, Qld, Australia; Crowe Associates Ltd, Thame, Oxon, England; Denver Hlth, Dept Med Pulm Sci & Crit Care, Aurora, CO USA; Univ Colorado Anschutz, Sch Med Denver, Aurora, CO USA; Cochrane, Dept Editorial & Methods, London, England; Univ Oxford, Nuffield Dept Med, Oxford, England; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Univ Chile, Dept Internal Med, Fac Med, Santiago, Chile; Jonze Soc, Brisbane, Qld, Australia; Univ Toronto, Dept Surg, Toronto, ON, Canada; Telethon Kids Inst, Perth, WA, Australia; Perth Childrens Hosp, Dept Infect Dis, Perth, WA, Australia; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada; Univ Witwatersrand, Dept Med, Div Crit Care & Pulmonol, Charlotte Maxeke Johannesburg Acad Hosp, Johannesburg, South Africa; Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa; Univ Cambridge, Dept Med, Cambridge, England; CHU Lille, Crit Care Ctr, F-59000 Lille, France; Lille Univ, F-59000 Lille, France; Univ Nova Lisboa, Nova Med Sch, Sao Francisco Xavier Hosp, CHLO,CHRC,Polyvalent Intens Care Unit, Lisbon, Portugal; OUH Odense Univ Hosp, Ctr Clin Epidemiol, Odense, Denmark; OUH Odense Univ Hosp, Res Unit Clin Epidemiol, Odense, Denmark; Jena Univ Hosp, Dept Anesthesiol & Intens Care, Jena, Germany; Peking Univ Third Hosp, Dept Resp Med, Beijing, Peoples R China; Univ Nottingham, Evidence Based Child Hlth Grp, Nottingham, England; Univ Bari, Dept Emergency & Organ Transplantat, Bari, Italy; Univ Barcelona, Hosp Clin, Dept Pulmonol, CIBERES,IDIBAPS, Barcelona, Spain; Univ Liverpool, Dept Biostat, Liverpool, Merseyside, England; Baylor Coll Med, Sect Infect Dis Dept Med, Natl Sch Trop Med, Houston, TX 77030 USA; Tianjin Univ Tradit Chinese Med, Evidence Based Med Ctr, Tianjin, Peoples R China ⓘ McGee, Richard/C-6117-2009; Craig, Jonathan/E-2813-2013; Smyth, Alan/MFJ-6463-2025; Woc-Colburn, Laila/U-7357-2019; Viecelli, Andrea/G-6966-2017; Morris, Andrew/B-8644-2012; Douglas, Ivor/AAC-6245-2021; Zhang, Junhua/AAZ-7434-2021; Scholes-Robertson, Nicole/KQU-4216-2024; Manera, Karine/ABH-9074-2020; Teixeira-Pinto, Armando/H-7947-2013; Williamson, Paula/B-6425-2016; Piva, Simone/E-1902-2014; Flemyng, Ella/HPD-8542-2023; Gonzalez, Andrea/HDM-9987-2022; Azevedo, Luciano/H-2652-2012; Povoa, Pedro/I-1669-2013; Snelling, Tom/Y-2162-2019; McKenzie, Anne/K-5912-2015; Torres, Antoni/H-6128-2017; , Paula/B-6425-2016; Lee, Jaehee/S-1697-2018; Lee, Yoojin/AAB-9799-2022; Peter, Horby/D-1585-2013; Cho, Yeoungjee/G-6176-2013 ⓘ 23020354400; 7402852244; 7005936833; 57208129702; 7003508148; 37109443800; 7102026332; 35182599800; 57189073773; 36088780600; 7005619134; 56850401300; 57191337554; 57218999768; 34975069600; 36004603200; 13805476000; 57219456204; 6602282714; 57219456938; 18536499900; 57219087890; 35983718700; 57193948923; 56288247700; 7401670721; 6603492314; 59157733200; 6602214576; 6602772147; 8641382000; 7801690639; 15133087500; 7103344712; 16032438700; 36057430000; 6602574836; 57205521091; 7402442902; 38362587800; 24774575800; 57197397371; 23007146500; 55720332300; 7401926037 ⓘ Allison.tong@sydney.edu.au; ⓘ CRITICAL CARE MEDICINE ⓘ CRIT CARE MED ⓘ 0090-3493 1530-0293 48 11 SCIE CRITICAL CARE MEDICINE ⓘ 2020 7.598 15.3 2.65 2025-06-25 ⓘ 46 48 clinical trial; coronavirus; critical care; infection; patients; sepsis ⓘ MANAGEMENT ⓘ clinical trial; coronavirus; critical care; infection; patients; sepsis ⓘ Adult; Aged; Betacoronavirus; Coronavirus Infections; Female; Health Services Accessibility; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Research Design; Symptom Assessment; adult; aged; Betacoronavirus; Coronavirus infection; female; health care delivery; human; male; methodology; middle aged; organization and management; pandemic; randomized controlled trial (topic); symptom assessment; virus pneumonia ⓘ English 2020 2020-11 10.1097/ccm.0000000000004585 ⓘ 바로가기 바로가기 바로가기 바로가기
페이지 이동: